Compare CDIO & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDIO | JAGX |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | 17 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 4.9M |
| IPO Year | 2021 | 2014 |
| Metric | CDIO | JAGX |
|---|---|---|
| Price | $2.05 | $0.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 43.0K | ★ 160.3K |
| Earning Date | 05-13-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.42 |
| EPS | ★ N/A | N/A |
| Revenue | $14,825.00 | ★ $11,511,000.00 |
| Revenue This Year | $171,906.75 | $61.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.97 | $0.22 |
| 52 Week High | $7.91 | $8.00 |
| Indicator | CDIO | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 57.98 | 33.57 |
| Support Level | $1.63 | $0.60 |
| Resistance Level | $2.22 | $1.04 |
| Average True Range (ATR) | 0.21 | 0.11 |
| MACD | 0.04 | 0.06 |
| Stochastic Oscillator | 65.43 | 38.71 |
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.